FLT3 and acute myeloid leukemia: Elevated FLT3-ITD plasma membrane expression levels following the use of TKIs have been reported to enhance the efficacy of chimeric antigen receptor T-cell therapy and antigen-dependent cytotoxicity based on anti-FLT3 compounds [23], suggesting that combining TKIs with immunotherapy may help improve prognosis for AML patients.